PRODUCT

VIP

No short description available.

Molecular Info

Chain Length:28 amino acids
Sequence Type:Linear neuropeptide
Molecular Weight:3326.8 Da
Amino Acid Sequence:His-Ser-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn-NH2
Modification:C-terminal amidation for stability

Research Indications

Inflammatory

effective

CIRS (Mold/Biotoxin Illness)
Final step in Shoemaker Protocol. Corrects inflammatory markers (TGF-β1, C4a, MMP9) refractory to other therapies. Over 10,000 patients treated safely.
Autoimmune Disease
Completely prevented joint destruction in experimental arthritis. Downregulates both inflammatory and autoimmune disease components.
Respiratory Inflammation
Bronchodilatory and anti-inflammatory effects. Studied in asthma, COPD, sarcoidosis, and COVID-19 ARDS.

Neurological

effective

Neuroprotection
Protects neurons from oxidative stress and inflammation. Improved memory in Alzheimer's models via intranasal delivery.
Circadian Regulation
Critical for SCN function and circadian rhythms. May improve sleep-wake cycles and hormonal rhythms.
Learning and Memory
VIP and VPAC receptors implicated in cognitive function. VPAC2 linked to schizophrenia susceptibility.

Vascular

effective

Pulmonary Hypertension
Selective pulmonary vasodilator. VIP deficiency causes PAH in animal models. Clinical studies show hemodynamic improvement.
COVID-19 ARDS
Phase 2b/3 trial: 2-fold increased 60-day survival, 10-fold for mechanically ventilated. Reduced IL-6 inflammatory marker.
Vascular Health
One of most potent endogenous vasodilators. Regulates blood flow and vascular tone throughout body.

Interactions

BPC-157

Compatible

Complementary anti-inflammatory mechanisms - VIP modulates immune response while BPC-157 promotes tissue healing

Thymosin Alpha-1

Synergistic

Both are immunomodulatory peptides that may complement each other in regulating immune function

LL-37

Compatible

Different mechanisms - VIP is anti-inflammatory while LL-37 is antimicrobial. May work together in CIRS protocols

KPV

Synergistic

Both have anti-inflammatory properties through different pathways (VIP via VPAC receptors, KPV via melanocortin system)

Selank

Compatible

Both have anxiolytic and immunomodulatory effects through different receptor systems

DSIP

Compatible

Both involved in circadian regulation - VIP in suprachiasmatic nucleus, DSIP in sleep induction

Cerebrolysin

Similar

Cerebrolysin contains VIP-like peptide fragments. Both are neuroprotective with overlapping mechanisms

GHK-Cu

Compatible

Complementary - VIP for systemic immune regulation, GHK-Cu for tissue remodeling and copper delivery

Dosage Protocols

Starting / Assess tolerance:10-30mcg1x daily
Standard protocol:200mcg (0.2mg)5x weekly (Mon-Fri)
Weekly total:1mg/weekSplit across 5 doses
Cycle protocol:200mcg3 months on, 1 month off

Route:injectable

Reconstitution

Clean work area and hands thoroughly
Add 5mL BAC water to 5mg vial = 1mg/mL (1000mcg/mL)
At 1mg/mL: 0.2mL (20 units) = 200mcg standard dose
Inject slowly down vial side (not directly onto powder)
Gently swirl until dissolved (never shake)
5mg vial at 200mcg/dose = approximately 25 doses
Store reconstituted in refrigerator at 2-8°C

Route:injectable

VIP

Resources

Categories

Company